SOUTH SAN FRANCISCO, Calif.,
Feb. 17, 2021 /PRNewswire/
-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic
lethality-focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
the appointment of Susan Kelley,
M.D., to its Board of Directors.
Dr. Kelley brings over 25 years of experience in oncology drug
research and development to IDEAYA. Most recently she served as
Chief Medical Officer of the Multiple Myeloma Research Consortium
(MMRC) where she led the strategic design and management of
clinical trials in North America.
Prior to the MMRC, she held positions of increasing responsibility
at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma,
including Vice President, Global Clinical Development and
Therapeutic Area Head – Oncology, where she led the team
responsible for the development and worldwide regulatory approval
of Nexavar® (sorafenib). Prior to joining Bayer, Dr. Kelley worked
at Bristol-Myers Squibb in Oncology and Immunology drug
development, ultimately serving as Executive Director, Oncology
Clinical Research, at the Bristol-Myers Squibb Pharmaceutical
Research Institute. She serves or has served as a member of the
Board of Directors at multiple publicly traded companies including
Deciphera Pharmaceuticals, Daré Bioscience, VBL Therapeutics Ltd,
ArQule and Immune Design. Dr. Kelley received her M.D. from
Duke University School of Medicine. She
was a Fellow in Medical Oncology and Clinical Fellow in Medicine at
Dana-Farber Cancer Institute, Harvard Medical
School, and a Fellow in Medical Oncology and Pharmacology at
Yale University School of Medicine,
where she also served as a Clinical Assistant Professor of
Medicine.
"Susan's expertise in clinical oncology will be invaluable as we
advance the Phase 1 IDE397 program in MTAP-deletion, evaluate
potential Phase 2 expansion for the IDE196 / binimetinib
combination, and target to select a Development Candidate for the
potential first-in-class PARG Synthetic Lethality program this
year," said Yujiro S. Hata,
President and Chief Executive Officer, at IDEAYA
Biosciences.
"I am excited to join IDEAYA as the company advances a broad
preclinical and clinical stage precision medicine oncology
pipeline, including several potential first-in-class Synthetic
Lethality programs with compelling biomarker hypotheses, and the
kinase inhibitor IDE196, an area in which I gained clinical
experience through the development of various kinase inhibitors,
including Nexavar®," said Dr. Kelley.
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality-focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to (i) the advancement of IDE397, (ii) the
timing for selection of a development candidate for PARG, and (iii)
the potential first-in-class and best-in-class status of
programs. Such forward-looking statements involve substantial
risks and uncertainties that could cause IDEAYA's preclinical and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the drug development process, including IDEAYA's programs' early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, IDEAYA's ability to successfully
establish, protect and defend its intellectual property, the
effects on IDEAYA's business of the worldwide COVID-19 pandemic,
and other matters that could affect the sufficiency of existing
cash to fund operations. IDEAYA undertakes no obligation to update
or revise any forward-looking statements. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the business of IDEAYA in general, see
IDEAYA's recent Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic
reports filed with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-susan-l-kelley-md-an-industry-veteran-in-medical-oncology-and-clinical-development-to-its-board-of-directors-301229557.html
SOURCE IDEAYA Biosciences, Inc.